Reps will tout new evidence that Fosamax increases bone density better than Actonel
December 2004
Reps will tout new evidence that Fosamax increases bone density better than Actonel in postmenopausal women.
But this is only part of the story.
It's true that a new study suggests Fosamax (alendronate) increases bone density of the hip by 3.4% in one year... compared to only 2.1% for Actonel (risedronate).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote